Samsung Biologics Co.,Ltd.
207940
주식 순위
#498
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon,... Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
주가
$1,028.49
시가총액
$47.88B
변동 (1일)
-3.67%
변동 (1년)
-18.37%
국가
KR
거래 Samsung Biologics Co.,Ltd. (207940)
카테고리
Healthcare
Samsung Biologics Co.,Ltd. (207940)의 EPS
September 2026 기준 EPS TTM: $29.29
Samsung Biologics Co.,Ltd.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $29.29입니다. 2024년 말에는 회사의 EPS가 $15.92였으며, 이는 2023년의 EPS $14.31와 증가입니다.
Samsung Biologics Co.,Ltd.의 EPS 기록 (2014 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $29.29 | 9.66% |
| 2025 | $26.71 | 67.81% |
| 2024 | $15.92 | 11.22% |
| 2023 | $14.31 | 2.67% |
| 2022 | $13.94 | 83.14% |
| 2021 | $7.61 | 49.15% |
| 2020 | $5.10 | 26.32% |
| 2019 | $4.04 | -12.69% |
| 2018 | $4.63 | -321.12% |
| 2017 | $-2.09 | -46.75% |
| 2016 | $-3.93 | -110.46% |
| 2015 | $37.57 | -1,964.20% |
| 2014 | $-2.02 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $17.32 | -40.86% |
US
|
|
| $-7.98 | -127.25% |
US
|
|
| $-5.29 | -118.06% |
AU
|
|
| $13.70 | -53.22% |
BE
|
|
| $27.74 | -5.29% |
NL
|
